Clinical Trials on Hepatitis A Virus in Japan

Total 435 results

Kyushu University

Unknown

PEG-IFN Plus Ribavirin Combination Therapy for Older Patients

Hepatitis C Virus

Japan
AbbVie

Completed

Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6

Hepatitis C Virus (HCV)

Japan
Novartis

Completed

Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients

Chronic Hepatitis C

Japan
Norte Study Group
Merck Sharp & Dohme LLC

Unknown

Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Kyoto University

Completed

Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Kyoto University

Completed

Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients

Hepatitis B

Japan
Bristol-Myers Squibb

Completed

Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Chronic Hepatitis C (CHC)

Japan
Mitsubishi Tanabe Pharma Corporation
Toray Industries, Inc

Completed

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Chronic Hepatitis C(CHC)

Japan
Japan Liver Oncology Group

Unknown

Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease (FIBROELAST)

Chronic Hepatitis B | Chronic Hepatitis C

Japan
Chugai Pharmaceutical

Completed

Trial of Pegasys® in Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
GlaxoSmithKline

Completed

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs

Hepatitis B, Chronic

Japan
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Hepatitis C | Pharmacokinetics

Japan
Kindai University

Unknown

Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography (PICTURE)

Chronic Hepatitis B | Chronic Hepatitis C

Japan
GlaxoSmithKline

Completed

A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B

Hepatitis B, Chronic

Japan
Boehringer Ingelheim

Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Hepatitis C, Chronic

Japan
Astellas Pharma Inc
Schering-Plough

Completed

Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

Hepatitis C

Japan
Kiminori Kimura, MD
Japan Agency for Medical Research and Development; Prism Pharma Co., Ltd.; National... and other collaborators

Completed

Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

Hepatitis B | Hepatitis C | Liver Cirrhoses

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

Japan
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PENGUIN)

Hepatitis B, Chronic

Taiwan, Poland, Japan, New Zealand
Chugai Pharmaceutical

Completed

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)

Liver Cirrhosis | Chronic Hepatitis C

Japan
GlaxoSmithKline

Completed

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue

Hepatitis B, Chronic

Japan
GlaxoSmithKline

Completed

Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

Hepatitis C, Chronic

Japan
Bristol-Myers Squibb

Completed

An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

Hepatitis C Infection

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients (DRAGON)

Hepatitis C, Chronic

Japan
Janssen Research & Development, LLC

Terminated

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection (PENGUIN-2)

Hepatitis B, Chronic

Taiwan, Spain, Canada, Poland, United States, Japan
GlaxoSmithKline

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects

Hepatitis B

Singapore, China, Hong Kong, Japan, Korea, Republic of, Philippines
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Hepatitis C Virus Infection

Japan
Japan Liver Oncology Group

Unknown

Sonazoid Enhanced Liver Cancer Trial for Early Detection

Liver Cirrhosis | Hepatitis B | Hepatocellular Carcinoma | Hepatitis C

Japan
Stanford University
Gilead Sciences

Completed

Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

Hepatitis B, Chronic

United States, Taiwan, Japan, Korea, Republic of
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Hepatitis C, Chronic

Japan
GlaxoSmithKline

Recruiting

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) (B-Well 1)

Chronic Hepatitis B

Italy, Japan, Spain, Korea, Republic of, Argentina, Canada, France, Poland
Bristol-Myers Squibb

Completed

Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy

Chronic Hepatitis B

Japan
Bristol-Myers Squibb

Completed

A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting

Hepatitis B Virus

Japan
Komagome Hospital
Japan Agency for Medical Research and Development; Prism Pharma Co., Ltd.

Completed

An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis

Hepatitis C Virus-infected Cirrhosis

Japan
Komagome Hospital
Japan Agency for Medical Research and Development; Prism Pharma Co., Ltd.

Completed

A Follow-up Evaluation Study of PRI-724-1101

Hepatitis C Virus-infected Cirrhosis

Japan
Novartis Pharmaceuticals

Active, not recruiting

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER)

Autoimmune Hepatitis

United States, Belgium, Germany, United Kingdom, Spain, Switzerland, Argentina, Canada, Japan, Czechia
AbbVie

Completed

The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects

Hepatitis C Virus

Japan

3

Subscribe